Health · Pharma & Biotech · 1 hr ago
Experimental weight-loss drug led to average 17.7% loss in 48-week trial
A weekly experimental injection called ribupatide helped adults with overweight or obesity lose weight in a trial led by researchers from Fudan University in Shanghai.
The study included 567 people, who received one of three doses of the drug or a dummy injection.
After 48 weeks, participants on the highest dose had lost an average of 17.7% of their starting weight, compared with 1.4% among those given the dummy treatment.
Ribupatide works by mimicking two hormones that help regulate appetite and blood sugar, in a way similar to Mounjaro.
The trial found that weight loss had not clearly levelled off among people on the two highest doses when it ended.
Nausea, vomiting and diarrhoea were common, affecting about half of those on the lowest dose and about two-thirds on the highest, though most cases were mild or moderate.
The results suggest ribupatide could become a rival to existing weight-loss injections, but it has not been directly compared with Wegovy or Mounjaro.
Phase three trials of the drug have begun recruiting patients in Britain.
Ribupatide, an experimental weekly weight-loss injection, was linked to average weight loss of 17.7% after 48 weeks at the highest dose in a trial.
The study included 567 overweight or obese adults and compared three ribupatide doses with a placebo.
Participants receiving the two highest doses were still losing weight when the study ended.
The most common side effects were stomach and digestive problems, usually mild or moderate.
Researchers also reported improvements in blood pressure, blood sugar control and cholesterol measurements.
- Who
- Researchers from Fudan University in Shanghai studied 567 overweight or obese adults.
- What
- A trial tested weekly injections of ribupatide at three doses against a dummy placebo.
- When
- Results were reported after 48 weeks. The article was published on November 15, 2026.
- Where
- The study was conducted by researchers from Fudan University in Shanghai. The trial location is not stated.
- Why
- To test the weight-loss effects and other health effects of ribupatide.
This story does not have two clearly opposing sides.
Participants completed the trial period, with those on the two highest doses still losing weight.
The Daily Mail published its report on the trial findings.
- Participants
- 567 overweight or obese adults
- Trial duration
- 48 weeks
- Highest dose
- 6mg weekly
- Average weight loss at 6mg
- 17.7%
- Placebo weight loss
- 1.4%
What people are saying
Reductions in body weight at week 48 were 16.4 per cent and 17.7 per cent with ribupatide 4mg and 6mg, respectively, and weight loss had not clearly plateaued in either group